CANCER:

Pancreatic Ductal Adenocarcinoma

Related cancers:

‹

Pancreatic Cancer (342)

Pancreatic Adenocarcinoma (51)

Pancreatic Cancer (342)

Pancreatic Adenocarcinoma (51)

›

No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	SBP-101 Sensitive: B - Late Trials	SBP-101 Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: B - Late Trials	gemcitabine Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine + capecitabine Sensitive: B - Late Trials	gemcitabine + capecitabine Sensitive: B - Late Trials
CCL11 overexpression CCL11 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CCL11 overexpression CCL11 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	tertomotide Sensitive: B - Late Trials	tertomotide Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CEND-1 Sensitive: B - Late Trials	CEND-1 Sensitive: B - Late Trials
KRAS wild-type KRAS wild-type	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS wild-type KRAS wild-type	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials	gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials
KRAS wild-type KRAS wild-type	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS wild-type KRAS wild-type	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	5-fluorouracil + oxaliplatin Sensitive: B - Late Trials	5-fluorouracil + oxaliplatin Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria
HGF-H HGF-H	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	HGF-H HGF-H	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials	FOLFIRINOX Resistant: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials	ipilimumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation + BRCA2 mutation BRCA1 mutation + BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA1 mutation + BRCA2 mutation BRCA1 mutation + BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
FANCF mutation FANCF mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FANCF mutation FANCF mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
MSH2 mutation MSH2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSH2 mutation MSH2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
DDR DDR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	DDR DDR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials
C3M/PRO-C3 ratio elevation C3M/PRO-C3 ratio elevation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	C3M/PRO-C3 ratio elevation C3M/PRO-C3 ratio elevation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PEGPH20 Sensitive: C3 – Early Trials	PEGPH20 Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials	cisplatin + gemcitabine Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials	cisplatin + gemcitabine Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials	cisplatin + gemcitabine Sensitive: C3 – Early Trials
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	leucovorin calcium Resistant: C3 – Early Trials	leucovorin calcium Resistant: C3 – Early Trials
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	5-fluorouracil Resistant: C3 – Early Trials	5-fluorouracil Resistant: C3 – Early Trials
GATA6 expression GATA6 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GATA6 expression GATA6 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials	gemcitabine Resistant: C3 – Early Trials
LAMC2 overexpression LAMC2 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	LAMC2 overexpression LAMC2 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials	gemcitabine Resistant: C3 – Early Trials
ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	durvalumab + gemcitabine + CP-675206 Sensitive: C3 – Early Trials	durvalumab + gemcitabine + CP-675206 Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ARID1A mutation ARID1A mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PD-L1 expression PD-L1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C3 – Early Trials	pembrolizumab + trametinib Sensitive: C3 – Early Trials
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials	FOLFIRINOX Resistant: C3 – Early Trials
MUC1 underexpression MUC1 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MUC1 underexpression MUC1 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: C3 – Early Trials	gemcitabine Sensitive: C3 – Early Trials
CLDN18.2 positive CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CLDN18.2 positive CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CT041 Sensitive: C3 – Early Trials	CT041 Sensitive: C3 – Early Trials
CAV1 overexpression CAV1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CAV1 overexpression CAV1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Resistant: C3 – Early Trials	gemcitabine + albumin-bound paclitaxel Resistant: C3 – Early Trials
MAP2K1 mutation MAP2K1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MAP2K1 mutation MAP2K1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials	avelumab + binimetinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials	avelumab + binimetinib Sensitive: C3 – Early Trials
MAP2K2 mutation MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MAP2K2 mutation MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials	avelumab + binimetinib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PIK3CA mutation PIK3CA mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials	avelumab + binimetinib Sensitive: C3 – Early Trials
RNF43 mutation RNF43 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	RNF43 mutation RNF43 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials	avelumab + binimetinib Sensitive: C3 – Early Trials
KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MRTX849 Sensitive: C3 – Early Trials	MRTX849 Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
KRAS mutation + PD-L1 expression KRAS mutation + PD-L1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS mutation + PD-L1 expression KRAS mutation + PD-L1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C3 – Early Trials	pembrolizumab + trametinib Sensitive: C3 – Early Trials
ATP1B1-NRG1 fusion ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ATP1B1-NRG1 fusion ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	afatinib Sensitive: C4 – Case Studies	afatinib Sensitive: C4 – Case Studies
APP-NRG1 fusion APP-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	APP-NRG1 fusion APP-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	afatinib Sensitive: C4 – Case Studies	afatinib Sensitive: C4 – Case Studies
FGFR1 T141R FGFR1 T141R	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FGFR1 T141R FGFR1 T141R	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	crizotinib Resistant: C4 – Case Studies	crizotinib Resistant: C4 – Case Studies
FGFR1 T141R FGFR1 T141R	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FGFR1 T141R FGFR1 T141R	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	alectinib Sensitive: C4 – Case Studies	alectinib Sensitive: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	lorlatinib Sensitive: C4 – Case Studies	lorlatinib Sensitive: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C4 – Case Studies	FOLFIRINOX Resistant: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	alectinib Resistant: C4 – Case Studies	alectinib Resistant: C4 – Case Studies
MSI-H/dMMR + TMB-H + PD-L1 overexpression MSI-H/dMMR + TMB-H + PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSI-H/dMMR + TMB-H + PD-L1 overexpression MSI-H/dMMR + TMB-H + PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
BRCA1 mutation + TMB-H BRCA1 mutation + TMB-H	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA1 mutation + TMB-H BRCA1 mutation + TMB-H	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + olaparib Sensitive: C4 – Case Studies	pembrolizumab + olaparib Sensitive: C4 – Case Studies
BRAF V600E BRAF V600E	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRAF V600E BRAF V600E	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	trametinib + vemurafenib Sensitive: C4 – Case Studies	trametinib + vemurafenib Sensitive: C4 – Case Studies
TLE2 overexpression TLE2 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	TLE2 overexpression TLE2 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: D – Preclinical	gemcitabine Sensitive: D – Preclinical
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BAL3833 Sensitive: D – Preclinical	BAL3833 Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GANT1 Sensitive: D – Preclinical	GANT1 Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GANT61 Sensitive: D – Preclinical	GANT61 Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical	Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cyclopamine Sensitive: D – Preclinical	cyclopamine Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	sonidegib Sensitive: D – Preclinical	sonidegib Sensitive: D – Preclinical
ASS1 underexpression ASS1 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ASS1 underexpression ASS1 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	panobinostat + pegargiminase Sensitive: D – Preclinical	panobinostat + pegargiminase Sensitive: D – Preclinical
TMB-L TMB-L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	TMB-L TMB-L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	trametinib + Torin1 Sensitive: D – Preclinical	trametinib + Torin1 Sensitive: D – Preclinical
MUC1 overexpression MUC1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MUC1 overexpression MUC1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BBI608 Sensitive: D – Preclinical	BBI608 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CDKN2A deletion CDKN2A deletion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BET inhibitor + CDK inhibitor Sensitive: D – Preclinical	BET inhibitor + CDK inhibitor Sensitive: D – Preclinical
TP53 mutation TP53 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	TP53 mutation TP53 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FL118 Sensitive: D – Preclinical	FL118 Sensitive: D – Preclinical
DDX5 overexpression DDX5 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	DDX5 overexpression DDX5 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FL118 Sensitive: D – Preclinical	FL118 Sensitive: D – Preclinical
GLI1 expression GLI1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GLI1 expression GLI1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	sonidegib Sensitive: D – Preclinical	sonidegib Sensitive: D – Preclinical
SIRT1 overexpression SIRT1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	SIRT1 overexpression SIRT1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gefitinib Sensitive: D – Preclinical	gefitinib Sensitive: D – Preclinical
BRCA mutation BRCA mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA mutation BRCA mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PARP inhibitor Sensitive: D – Preclinical	PARP inhibitor Sensitive: D – Preclinical
KRAS G12D + Chr del(9)(p21) KRAS G12D + Chr del(9)(p21)	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS G12D + Chr del(9)(p21) KRAS G12D + Chr del(9)(p21)	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	palbociclib Resistant: D – Preclinical	palbociclib Resistant: D – Preclinical
CD276 expression CD276 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CD276 expression CD276 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical
SLC3A2-NRG1 fusion SLC3A2-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	SLC3A2-NRG1 fusion SLC3A2-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MM-121 Sensitive: D – Preclinical	MM-121 Sensitive: D – Preclinical
ATP1B1-NRG1 fusion ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ATP1B1-NRG1 fusion ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MM-121 Sensitive: D – Preclinical	MM-121 Sensitive: D – Preclinical
KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	sotorasib + selinexor Sensitive: D – Preclinical	sotorasib + selinexor Sensitive: D – Preclinical
KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	selinexor + MRTX1257 Sensitive: D – Preclinical	selinexor + MRTX1257 Sensitive: D – Preclinical
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	RMC-6236 Sensitive: D – Preclinical	RMC-6236 Sensitive: D – Preclinical
MYC overexpression MYC overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MYC overexpression MYC overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	WB100 Sensitive: D – Preclinical	WB100 Sensitive: D – Preclinical
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ASN007 + ERAS-601 Sensitive: D – Preclinical	ASN007 + ERAS-601 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CDKN2A deletion CDKN2A deletion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	palbociclib + JQ-1 Sensitive: D – Preclinical	palbociclib + JQ-1 Sensitive: D – Preclinical
KRAS G12D KRAS G12D	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS G12D KRAS G12D	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	trametinib + BI-3406 Sensitive: D – Preclinical	trametinib + BI-3406 Sensitive: D – Preclinical
KRAS G12D KRAS G12D	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS G12D KRAS G12D	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MRTX1133 + BI 894999 + dBET6 Sensitive: D – Preclinical	MRTX1133 + BI 894999 + dBET6 Sensitive: D – Preclinical

Pancreatic Ductal Adenocarcinoma

Associations(83)

Associations
(83)